ReviewWorld journal of gastroenterology2014
MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Serum MicroRNA-196, -200 and -423 Improve Diagnostics and Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.Physiological research · 2025Article
- Role of microRNAs in response to cadmium chloride in pancreatic ductal adenocarcinoma.Archives of toxicology · 2022Article
- Article
- Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2020Review
- Present and Future of Endoscopic Ultrasound-Guided Tissue Acquisition in Solid Pancreatic Tumors.Clinical endoscopy · 2019Article
- Role of non-coding RNA in pancreatic cancer.Oncology letters · 2019Review
- EZH2-Mediated microRNA-139-5p Regulates Epithelial-Mesenchymal Transition and Lymph Node Metastasis of Pancreatic Cancer.Molecules and cells · 2018Article
- Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma.Cancers · 2018Article
- miR-136 Inhibits Malignant Progression of Hepatocellular Carcinoma Cells by Targeting Cyclooxygenase 2.Oncology research · 2018Article
- Curcumin induces apoptotic cell death in human pancreatic cancer cells via the miR-340/XIAP signaling pathway.Oncology letters · 2017Article
- Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.Journal of cancer research and clinical oncology · 2017Article
- Article
- MicroRNA-127 is aberrantly downregulated and acted as a functional tumor suppressor in human pancreatic cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- MicroRNA-21 promotes phosphatase gene and protein kinase B/phosphatidylinositol 3-kinase expression in colorectal cancer.World journal of gastroenterology · 2016Article
- MicroRNA aberrations: An emerging field for gallbladder cancer management.World journal of gastroenterology · 2016Review
- Restoration of miR-20a expression suppresses cell proliferation, migration, and invasion in HepG2 cells.OncoTargets and therapy · 2016Article
- Deregulation of MicroRNA-375 inhibits cancer proliferation migration and chemosensitivity in pancreatic cancer through the association of HOXB3.American journal of translational research · 2016Article
- Targeting MUC4 in pancreatic cancer: miRNAs.Oncoscience · 2015Article
- miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression.Molecular vision · 2015Article
- Bioinformatics identification of potentially involved microRNAs in Tibetan with gastric cancer based on microRNA profiling.Cancer cell international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite tremendous efforts from scientists and clinicians worldwide, pancreatic adenocarcinoma (PDAC) remains a deadly disease due to the lack of early diagnostic tools and reliable therapeutic approaches. Consequently, a majority of patients (80%) display an advanced disease that results in a low resection rate leading to an overall median survival of less than 6 months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are desperately needed to help alleviate the dismal prognosis of this cancer. In addition, the discovery of new therapeutic targets is mandatory to design effective treatments. In this review, we will highlight the translational studies demonstrating that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.